This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasm of adrenal gland
C3_ADRENAL_GLAND
adrenal gland neoplasm: A neoplasm (disease) that involves the adrenal gland.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
181 |
4. Check minimum number of eventsNone |
181 |
5. Include endpointsNone |
181 |
6. Filter based on genotype QC (FinnGen only) |
161 |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of adrenal gland
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of adrenal gland, including Hilmo
- Malignant neoplasm of endocrine gland
- Malignant neoplasm of endocrine gland, including Hilmo
- Solid cancers
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 161 | 80 | 81 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 58.29 | 54.89 | 61.64 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 171
- Matched controls
- 1710
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
505.5
131.5
116
7
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
359.5
84.8
79
*
H02AB09
ATC
hydrocortisone; systemic
32.4
77.1
54
24
130
Kela drug reimbursment
Malignant tumour
+∞
75.8
67
*
C74.0
ICD-10 Finland
Malignant neoplasm: Cortex of adrenal gland
+∞
72.1
64
*
C74.1
ICD-10 Finland
Malignant neoplasm: Medulla of adrenal gland
+∞
61.2
55
*
TPH07
NOMESCO Finland
Cathetrisation of artery
12.1
54.6
71
95
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
54.1
49
*
C74.9
ICD-10 Finland
Malignant neoplasm: Adrenal gland, unspecified
+∞
47.1
43
*
8700/3-C74.1
ICD-O-3
Pheochromocytoma, NOS, of medulla of adrenal gland
+∞
47.1
43
*
8700/3-C74.9
ICD-O-3
Pheochromocytoma, NOS, of adrenal gland, NOS
+∞
44.8
41
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
44.8
41
*
JN4AD
NOMESCO Finland
Body CT examination
13.9
39.8
41
38
8370/3-C74.0
ICD-O-3
Adrenal cortical carcinoma of cortex of adrenal gland
+∞
37.9
35
*
JN4BD
NOMESCO Finland
Extensive body CT
16.0
37.7
35
27
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
50.0
35.4
42
11
L01XX23
ATC
mitotane; oral
+∞
32.3
30
*
JN3AD
NOMESCO Finland
Abdominal CT examination
6.9
25.6
48
92
H02AB02
ATC
dexamethasone; systemic
51.6
25.5
30
7
A03FA01
ATC
metoclopramide; systemic, rectal
6.0
24.0
53
119
A04AA02
ATC
granisetron; systemic, transdermal
263.9
23.2
23
*
H02AA02
ATC
fludrocortisone; oral
92.6
22.3
24
*
A04AA01
ATC
ondansetron; systemic, rectal
20.4
21.5
32
19
WZC00
NOMESCO Finland
Treatment plan or consultation
4.4
20.4
85
315
WX402
NOMESCO Finland
General anaesthesia
4.5
19.7
68
218
WX302
NOMESCO Finland
Thoracal epidural anesthesy
17.9
19.3
30
20
XW000
NOMESCO Finland
Bone marrow biopsy
25.1
17.4
24
11
9500/3-C74.1
ICD-O-3
Neuroblastoma, NOS, of medulla of adrenal gland
+∞
16.9
16
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
7.1
16.5
27
44
WX408
NOMESCO Finland
General anesthesy, balanced
3.9
16.0
67
242
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
15.9
15
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
15.9
15
*
N02AA05
ATC
oxycodone; systemic
4.9
15.7
41
104
BC1AD
NOMESCO Finland
CT of adrenal glands
32.1
15.6
20
7
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.5
15.5
34
74
ZXE20
NOMESCO Finland
More than three and less than five hours
4.7
14.9
41
108
B01AB05
ATC
enoxaparin; parenteral
3.6
14.7
71
280
ZXE10
NOMESCO Finland
More than one and less than three hours
3.5
14.5
84
371
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.0
14.3
52
169
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
13.7
13
*
JN3CG
NOMESCO Finland
Extensive MRI examination of abdomen with high intensity magnet
151.5
13.7
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
13.5
100
507
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
13.1
13.3
23
20
WZC30
NOMESCO Finland
Teaching
4.2
13.3
43
128
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
12.7
12
*
Z31.5
ICD-10 Finland
Genetic counselling
5.9
11.9
23
44
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
11.6
11
*
BC5AQ
NOMESCO Finland
Chromaffine tissue SPECT with low dose CT
+∞
11.6
11
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
128.3
11.6
12
*
L03AA02
ATC
filgrastim; parenteral
128.3
11.6
12
*
BC1CD
NOMESCO Finland
Very extensive CT of adrenal glands
37.9
11.5
14
*
Z51.5
ICD-10 Finland
Palliative care
11.2
11.4
21
21
D41.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Kidney
17.0
11.1
17
11
XX3DW
NOMESCO Finland
Time consuming IT work
9.0
11.0
23
29
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
10.5
10
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
25.2
10.4
14
6
H03AA01
ATC
levothyroxine sodium; systemic
3.2
10.2
52
206
JN4CD
NOMESCO Finland
Very extensive body CT
21.6
10.0
14
7
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
4.7
9.7
24
57
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
9.6
36
117
WW500
NOMESCO Finland
Blood transfusion
13.4
9.6
16
13
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
105.6
9.5
10
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
9.5
9
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
9.5
9
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
9.5
9
*
JN3DG
NOMESCO Finland
Very extensive MRI examination with high intensity magnet
52.8
8.8
10
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
52.8
8.8
10
*
TPH90
NOMESCO Finland
Removal of fixed intravenous catheter
17.4
8.7
13
8
B01AB10
ATC
tinzaparin; parenteral
4.1
8.7
26
72
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
94.5
8.5
9
*
WF002
NOMESCO Finland
Radical radiotherapy
94.5
8.5
9
*
ZX120
NOMESCO Finland
Intravenous
4.6
8.5
21
50
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
8.4
8
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
8.4
8
*
WB123
NOMESCO Finland
Demanding adjuvant cytostatic therapy
+∞
8.4
8
*
L01BC06
ATC
capecitabine; oral
+∞
8.4
8
*
R11
ICD-10 Finland
Nausea and vomiting
3.6
8.3
30
95
WX404
NOMESCO Finland
Intravenous generell anesthesy
2.9
8.1
45
185
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.0
8.0
25
71
J01MA12
ATC
levofloxacin; systemic
3.0
7.9
40
156
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
47.2
7.8
9
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
14.2
7.5
12
9
L03AA13
ATC
pegfilgrastim; parenteral
83.6
7.5
8
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.4
7.4
75
414
A04AD12
ATC
aprepitant; systemic
+∞
7.3
7
*
8370/3-C74.9
ICD-O-3
Adrenal cortical carcinoma of adrenal gland, NOS
+∞
7.3
7
*
2533
FHL
Unilateral removal of additional egg
+∞
7.3
7
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
7.3
7
*
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
+∞
7.3
7
*
Z85.8
ICD-10 Finland
Personal history of malignant neoplasms of other organs and systems
+∞
7.3
7
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
7.3
7
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
7.3
7
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
7.3
7
*
WD135
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
7.3
7
*
A04AA55
ATC
palonosetron, combinations; systemic
+∞
7.3
7
*
8010/3-C74.9
ICD-O-3
Carcinoma, NOS, of adrenal gland, NOS
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
N02AA01
ATC
morphine; systemic, rectal
31.5
7.2
9
*
ZXE00
NOMESCO Finland
One hour or less
2.4
7.0
76
431
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
7.7
6.9
15
21
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
4.5
6.7
17
41
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
72.4
6.5
7
*
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.0
6.4
19
52
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
9.8
6.4
12
13
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.4
6.4
56
287
Y77
ICPC
Malignant neoplasm prostate
+∞
6.3
6
*
BC1BD
NOMESCO Finland
Extensive CT of adrenal glands
+∞
6.3
6
*
116
Kela drug reimbursment
Prostate cancer
+∞
6.3
6
*
BC5AN
NOMESCO Finland
Chromaffine and adrenergic tissue isotope imaging (MIBG)
+∞
6.3
6
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
6.3
6
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
V04CD01
ATC
metyrapone; oral
+∞
6.3
6
*
Z2221
NOMESCO Finland
Medical doctor
2.4
6.1
54
277
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
102
28
88.80
176.18
4.9
1.4
3.33
0.20
nmol/l
0.74
81
21
90
27
69.26
150.45
5.0
1.4
—
—
nmol/l
—
0
0
60
31
29.28
81.00
4.7
1.5
79.14
20.15
ng/l
2.82
60
31
45
16
37.81
68.90
1.3
1.2
—
—
—
0
0
65
7
148.02
64.33
4.9
3.1
5.17
5.47
nmol/l
—
65
7
124
585
5.07
21.83
4.5
2.6
—
—
estimate
—
0
0
35
63
6.73
19.59
3.4
1.8
3.40
2.55
ug/l
1.00
30
48
126
667
4.38
17.38
18.0
8.7
1.20
1.22
mmol/l
1.15
106
596
76
311
3.60
14.90
4.1
2.1
—
—
—
0
0
34
82
4.93
13.71
7.3
3.9
1.23
1.22
mmol/l
0.54
34
68
47
163
3.60
11.53
1.9
1.8
—
—
—
0
0
54
207
3.35
11.31
2.4
1.8
—
—
—
0
0
45
157
3.53
10.89
2.1
1.9
—
—
—
0
0
127
803
3.26
10.77
25.9
7.2
4.13
4.13
e9/l
0.00
112
685
41
137
3.62
10.57
20.8
15.4
25.20
24.56
mmol/l
0.39
41
137
29
76
4.39
10.45
1.7
1.2
—
—
—
0
0
39
127
3.68
10.44
2.2
2.8
0.22
0.21
g/l
0.37
33
114
80
401
2.87
10.32
4.6
3.5
0.26
0.28
e6/l
0.06
66
280
16
17
10.25
8.48
1.8
1.4
—
—
—
0
0
14
12
12.58
8.24
1.4
1.0
—
—
—
0
0
20
33
6.72
8.14
1.7
1.6
—
—
—
0
0
35
124
3.29
8.13
4.9
2.9
—
—
—
0
0
14
14
10.77
7.69
2.6
3.9
8.46
13.49
mu/l
1.21
14
14
19
32
6.54
7.64
1.8
1.7
—
—
—
0
0
14
15
10.05
7.44
1.7
1.2
—
—
—
0
0
68
361
2.47
7.29
2.3
2.3
2.58
2.63
mg/l
0.07
59
311
20
56
3.91
6.53
3.5
3.7
105.35
88.38
%
2.12
20
56
15
23
7.04
6.50
1.7
1.3
—
—
—
0
0
16
28
6.19
6.32
2.8
2.6
32.45
20.60
u/ml
0.26
11
20
16
30
5.77
6.02
1.5
1.3
—
—
—
0
0
9
6
15.72
5.97
6.4
6.8
—
—
—
0
0
43
205
2.47
5.65
2.7
2.8
26.33
23.07
%
0.47
43
196
142
1110
2.65
5.60
6.8
4.0
14.28
14.75
pmol/l
1.38
133
1024
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
33
5.24
5.59
1.5
4.1
0.26
0.33
iu/ml
0.46
11
18
21
69
3.33
5.43
1.9
1.6
—
—
—
0
0
15
41
3.91
5.05
1.1
1.3
—
—
—
0
0
45
238
2.21
4.60
2.9
2.7
12.88
13.67
umol/l
0.28
45
227
28
121
2.57
4.47
3.1
2.0
23.73
37.11
u/l
0.92
22
96
8
9
9.25
4.32
1.3
1.4
—
—
—
0
0
7
6
12.09
4.31
1.7
1.0
—
—
—
0
0
13
30
4.60
4.23
1.5
4.0
—
—
—
0
0
11
21
5.52
4.22
1.5
1.4
—
—
—
0
0
11
22
5.27
4.08
3.4
4.2
4.99
4.86
kpa
0.18
11
22
8
12
6.93
3.71
6.5
1.9
0.38
0.83
index
—
8
12
124
987
1.93
3.62
4.3
3.7
73.25
44.86
u/l
2.63
118
941
18
69
2.80
3.60
2.7
2.2
20.31
19.69
iu/l
0.02
12
52
9
17
5.52
3.56
1.1
1.2
—
—
—
0
0
13
37
3.72
3.49
1.7
2.1
176.25
281.78
u/ml
—
8
9
13
38
3.62
3.39
1.7
2.1
—
—
—
0
0
9
20
4.69
3.16
2.0
1.2
—
—
—
0
0
10
25
4.18
3.14
1.5
1.6
—
—
—
0
0
6
8
7.72
3.08
3.5
1.4
5.60
4.44
nmol/l
—
6
8
8
17
4.88
2.95
1.1
1.4
—
—
—
0
0
10
29
3.60
2.74
1.9
1.3
—
—
—
0
0
10
29
3.60
2.74
2.8
1.2
1.59
1.37
ratio
—
5
14
8
19
4.36
2.71
6.5
2.2
12.50
15.75
index
—
8
12
127
1063
1.76
2.64
5.1
4.5
15.93
10.81
mm/h
2.07
120
1001
7
15
4.82
2.62
2.3
1.1
—
—
—
0
0
43
270
1.79
2.60
4.5
3.2
0.30
0.78
e6/l
2.56
22
140
5
7
7.31
2.56
1.6
1.3
—
—
—
0
0
10
31
3.36
2.56
1.9
2.0
—
—
—
0
0
8
21
3.94
2.49
3.6
6.7
8.94
12.67
pmol/l
—
8
21
41
257
1.78
2.49
4.7
3.6
1.38
2.23
e6/l
0.34
20
128
19
91
2.22
2.44
4.0
2.6
60.89
68.88
ml/min/173m2
—
9
34
7
18
4.01
2.27
1.9
1.3
—
—
—
0
0
150
1341
1.97
2.24
7.2
4.9
1.81
1.97
mu/l
0.76
142
1237
8
24
3.44
2.21
1.1
1.3
—
—
—
0
0
24
134
1.92
2.08
28.7
5.0
24.85
23.82
mmol/l
0.76
24
134
7
20
3.60
2.08
1.9
1.4
—
—
—
0
0
58
419
1.58
2.04
4.0
3.2
0.00
0.00
estimate
-0.00
26
126
5
11
4.65
1.95
1.8
1.0
—
—
—
0
0
5
12
4.26
1.83
1.0
1.0
—
—
—
0
0
148
1341
1.77
1.78
5.2
4.9
5.84
5.96
mmol/l
0.70
143
1240
53
388
1.53
1.73
3.8
3.6
0.00
0.00
estimate
-0.00
27
138
75
595
1.46
1.64
2.0
2.0
88.30
97.03
pmol/l
0.71
35
286
58
438
1.49
1.62
2.7
3.3
2097.30
1217.77
ng/l
0.84
47
365
7
26
2.76
1.60
1.1
1.6
—
—
—
0
0
7
26
2.76
1.60
1.1
1.6
—
—
—
0
0
45
324
1.53
1.57
2.7
2.0
1.05
0.86
mg/l
0.37
33
255
9
38
2.44
1.48
1.6
1.9
0.91
0.73
nmol/l
—
9
33
47
350
1.47
1.39
3.3
2.7
316.52
353.25
umol/l
1.22
42
313
153
1426
1.69
1.30
34.1
12.9
31.15
22.64
mg/l
2.36
141
1120
38
276
1.48
1.27
5.9
3.7
177.33
309.33
ng/l
0.41
30
206
12
63
1.97
1.26
1.8
1.8
—
—
—
0
0
140
1283
1.50
1.24
35.6
12.0
82.19
83.14
ml/min/173m2
0.19
130
1169
78
650
1.37
1.21
2.6
2.0
1.66
1.39
mmol/l
1.27
72
570
65
528
1.37
1.17
5.0
3.5
30.11
44.79
ng/l
0.98
43
361
89
760
1.36
1.17
4.4
3.7
0.00
0.00
estimate
-0.00
29
148
91
780
1.36
1.16
4.5
3.7
0.00
0.02
estimate
0.50
25
142
5
20
2.54
1.16
8.2
2.9
9.80
10.35
mmol/l
—
5
20
16
97
1.72
1.11
2.0
2.3
—
—
—
0
0
7
32
2.24
1.09
1.4
1.8
—
—
—
0
0
89
769
1.33
1.04
4.4
3.7
0.00
0.00
estimate
-0.00
29
151
16
99
1.68
1.04
1.3
1.3
85.00
102.61
u/ml
—
7
37
7
34
2.10
1.04
2.1
2.3
127.00
132.40
g/l
—
7
25
67
559
1.33
0.99
3.9
3.4
0.00
0.02
estimate
0.74
27
131
6
118
0.49
0.98
1.8
1.9
3.33
3.53
mmol/l
—
6
93
14
85
1.70
0.97
2.0
2.1
—
—
—
0
0
8
43
1.90
0.88
1.5
1.6
—
0.07
—
0
10
157
1498
1.59
0.87
46.9
16.2
77.70
75.51
umol/l
0.37
157
1470
28
208
1.41
0.84
2.2
1.7
1345.14
1107.97
nmol/l
0.56
20
157
13
82
1.63
0.80
32.9
4.1
0.63
0.59
%
0.14
13
82
139
1306
1.34
0.76
5.1
4.4
1.47
1.28
mmol/l
1.56
130
1219
7
39
1.83
0.73
2.0
1.6
—
—
—
0
0
33
259
1.34
0.73
1.7
1.7
381.92
53182255.95
pmol/l
0.50
26
220
7
40
1.78
0.72
1.9
1.7
—
—
—
0
0
7
41
1.74
0.71
1.4
1.6
—
—
—
0
0
7
41
1.74
0.71
1.7
1.2
—
—
—
0
0
19
257
0.71
0.69
1.4
1.3
4.89
11.83
u/ml
—
7
100
57
488
1.25
0.66
4.4
4.1
23.79
43.69
mg/mmol
0.24
36
322
5
29
1.75
0.64
1.0
1.2
—
—
—
0
0
5
29
1.75
0.64
1.2
1.2
—
—
—
0
0
5
29
1.75
0.64
1.0
1.6
—
—
—
0
0
0
20
0.00
0.61
0.0
1.0
—
18.90
—
0
20
144
1377
1.29
0.54
5.7
5.3
4.77
4.59
mmol/l
1.07
137
1304
24
296
0.78
0.49
1.3
1.3
68.73
34.90
iu/ml
—
6
82
34
288
1.23
0.43
3.3
2.8
1.04
0.74
ug/l
0.54
21
176
27
323
0.81
0.43
3.6
3.2
1.02
1.02
kg/l
0.44
19
203
8
57
1.42
0.43
2.1
1.6
—
—
—
0
0
145
1398
1.24
0.42
6.3
5.9
2.69
2.71
mmol/l
0.09
138
1318
10
138
0.71
0.42
10.9
5.6
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
20
162
1.27
0.37
2.0
2.2
—
—
—
0
0
12
153
0.77
0.32
2.0
2.1
3.97
3.51
ratio
0.56
12
127
141
1373
1.15
0.25
5.7
5.2
1.47
1.44
mmol/l
0.30
133
1290
52
479
1.12
0.25
5.5
4.1
3.36
1.85
ug/l
0.62
43
430
21
181
1.18
0.24
2.1
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
5
69
0.72
0.17
1.4
1.6
652.92
825.76
mu/l
—
5
58
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
46
1.09
0.09
1.0
1.2
—
—
—
0
0
8
78
1.03
0.07
1.0
1.3
—
—
—
0
0
13
119
1.10
0.06
2.3
2.5
0.05
0.16
e6/l
1.34
13
114
11
120
0.91
0.05
1.5
1.5
—
—
—
0
0
21
201
1.05
0.03
1.3
1.4
—
—
—
0
0
38
388
0.97
0.02
1.4
1.6
0.77
2.29
u/ml
1.21
13
95
39
383
1.02
0.01
4.0
3.8
23.71
24.38
%
0.05
21
173
95
957
0.98
0.01
3.7
3.3
—
—
—
0
0
158
1581
0.99
0.00
58.5
20.4
38.24
40.68
%
6.07
158
1559
32
325
0.98
0.00
1.5
2.0
—
—
—
0
0
158
1582
0.98
0.00
55.2
20.0
128.04
136.91
g/l
8.34
158
1559
6
60
1.00
-0.00
1.2
1.1
1.57
1.48
g/l
—
6
60
0
7
0.00
-0.00
0.0
1.9
—
62.86
—
0
7
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
11
110
1.00
-0.00
1.1
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
1.67
—
0
7
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
-0.00
1.2
1.2
0.96
0.91
g/l
—
6
61
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
2.8
—
147.00
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
158
1580
1.00
-0.00
54.7
19.8
90.53
90.28
fl
0.28
158
1558
5
50
1.00
-0.00
1.2
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
41.60
—
0
6
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
6
0.00
-0.00
0.0
1.2
—
109.00
—
0
6
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: C3_ADRENAL_GLAND – Malignant neoplasm of adrenal gland
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).